Original Research
Published on 03 Apr 2020
ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor–Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy
in Women's Cancer
- 7,182 views
- 11 citations









